why choose us

First received: July 28, 2023

Clinical Trial: CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: B-Cell Non Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: Phase I Clinical Trial Evaluating the Safety and Efficacy of Point-of-care CAR-T-cell Therapy in the Treatment of Relapsed/Refractory CD19+ Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Brief Summary: Brief Summary: Cluster of differentiation 19 (CD19) is expressed on B cells.CD19+ tumor cells in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia can be targeted using T cells expressing CD19-specific chimeric antigen receptor (CAR).Objective: This study aims to evaluate the safety and efficacy of single-dose anti-CD19 CAR T-cell therapy in the treatment of relapsed/refractory CD19+ non-Hodgkin lymphoma and acute lymphoblastic leukemia.Eligibility: People aged 1 to 60 years with…

Read more